DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study.
Over 4 million cases of BCC and 1 million cases of SCC are diagnosed each year in the U.S., with more than 13 million surgical biopsies performed to diagnose these non-melanoma skin cancers. Carcinome™ is the third non-invasive skin cancer test being developed by DermTech using their proprietary molecular pathology platform technology.
“We are excited to complete this phase of the study and look forward to Carcinome’s™ full validation to successfully distinguish BCC and SCC from non-cancerous lesions, all with skin tissue collected non-invasively using adhesive patches,” said Zuxu Yao, PhD, DermTech’s Chief Scientific Officer and head of Research and Development.
About DermTech
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180529005035/en/
Contacts
DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
(858) 450-4222
sdion@dermtech.com
View this news release online at:
http://www.businesswire.com/news/home/20180529005035/en
